177Lu-PSMA-617 With Enzalutamide for mCRPC Boosts OS, QOL ...

177Lu-PSMA-617 With Enzalutamide for mCRPC Boosts OS, QOL ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

Staffing and certain compliance issues related to updated survey guidance coming in late March, particularly those that relate to patient discharges as ...

Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...

The following is a summary of “Multicentre cross-sectional study to assess nursing workload in Belgian emergency departments,” published in the February 2025 issue of Emergency Medicine Journal by ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...